Dyrk1B Activators

Dual specificity tyrosine-phosphorylation-regulated kinase 1B (DYRK1B) activators encompass a variety of chemical compounds that either directly enhance the kinase's phosphorylation activity or indirectly influence signaling pathways and cellular processes that lead to its functional activation. For instance, harmine and harmol are beta-carboline alkaloids that bind to the ATP-binding sites of DYRK1B, inhibiting its autophosphorylation but ultimately leading to an increase in the phosphorylation of other substrates. This paradoxical activation is a characteristic feature of some kinase inhibitors. In a similar vein, small molecule inhibitors such as INDY, Leucettine L41, and Meridianin C interact with the kinase's active site, which can result in an enhanced phosphorylation activity by stabilizing the enzyme in an active conformation or by increasing the phosphorylation of downstream targets.

Other compounds, while not directly interacting with DYRK1B, influence cellular components or signaling cascades that lead to the kinase's activation. For example, Tetrahydrocurcumin and ellagic acid interact with cellular signaling pathways that converge on DYRK1B, enhancing its activity. Purvalanol A and Roscovitine, known as cyclin-dependent kinase inhibitors, can have off-target effects that result in the modulation of cell cycle-related kinases, including DYRK1B, leading to an increase in its activity. Similarly, compounds like Epigallocatechin gallate (EGCG) and Quercetin, commonly found in natural products, have been observed to inhibit DYRK1B but also lead to an increase in its functional activity through complex feedback and regulatory mechanisms within the cell.